Tylogenin
Latest Information Update: 06 Jul 1998
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class Antiallergics; Antihistamines
- Mechanism of Action Histamine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypersensitivity
Most Recent Events
- 06 Jul 1998 Profile reviewed
- 06 Jul 1998 No-Development-Reported for Allergy in USA (Unknown route)
- 22 Jun 1995 Preclinical development for Allergy in USA (Unknown route)